Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.49 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.49 |
| ▸ | WNT3A | P56704 | 10/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 10/20 | 0.43 |
| ▸ | SPR | P35270 | 3/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31128515 | 0.84 | TNKS2 (0.50) | PARP1PARP15PARP3WNT3ATNKS2 | |
| SCHEMBL7776894 | 0.84 | TNKS2 (0.61) | PARP1PARP15PARP3WNT3ATNKS2 | |
| SCHEMBL31150947 | 0.77 | TNKS2 (0.38) | WNT3ATNKS2SPRALDH1A1TNKS | |
| SCHEMBL18689611 | 0.77 | TNKS2 (0.43) | WNT3ATNKS2SPRALDH1A1TNKS | |
| SCHEMBL18711685 | 0.77 | TNKS2 (0.38) | WNT3ATNKS2SPRTNKS | |
| SCHEMBL18701496 | 0.77 | TNKS2 (0.39) | WNT3ATNKS2SPRL3MBTL1TNKS | |
| SCHEMBL10150407 | 0.74 | PARP1 (0.59) | PARP1PARP15PARP3SPRALDH1A1 | |
| SCHEMBL18711836 | 0.74 | PARP1 (0.62) | PARP1PARP15PARP3TYMSALDH1A1 | |
| SCHEMBL12102083 | 0.73 | PARP1 (0.41) | PARP1PARP15PARP3TNKS2TYMS | |
| SCHEMBL3119493 | 0.72 | PARP1 (0.47) | PARP1PARP15PARP3TNKS2TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | PARP1 2611/4885PARP15 1362/4885PARP3 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.